Length of Stay with ACURATE neo vs. Evolut ™ R ACURATE neo Aortic Valve System – Clinical Data Clinical Highlights Study Design Routine use of the ACURATE neo self-expanding valve is associated with improved procedural outcomes and reduced post-operative length of stay: Insights from a single-center registry (ACURATE neo vs. Evolut R) Kotronias RA, Banning AP, Kharbanda RK. Oxford University Hospital. Presented at EuroPCR 2019 by R. A. Kotronias. Single-center study from Oxford, Great Britain, evaluating the impact of valve selection on procedural outcomes, length of stay (LoS), and 30-day mortality in 231 patients treated with either ACURATE neo (n = 143) or Evolut R (n = 88) between March 2017 and September 2018. ACURATE neo demonstrates reduced post-operative complications and permanent pacemaker rates and comparable mortality and stroke rates vs. Evolut R Improvements in procedural outcomes with ACURATE neo are associated with reductions in post-operative length of stay A multivariate linear regression model identified peri-procedural complications, pre-existing RBBB, and new permanent pacemaker implantation as independent predictors of post-operative length of stay. 3 3 3 2 2 In-hospital mortality 30-day mortality 0 Stroke 10 29 8 9 New PPI after TAVI 1 1 Life- threatening bleeding Major vascular complications ACURATE neo (n = 143) Evolut R (n = 88) ACURATE neo 0 1 2 3 4 5 6 7 8 9 10 Evolut R Post-Operative Length of Stay Procedural Outcomes Length of stay (days) % of patients aOR 0.16 (0.05–0.5) aOR 0.14 (0.01–0.68) aOR 0.14 (0.03–0.68) 30 35 20 25 15 10 5 0 All trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority product registrations. Not intended for use or distribution in France, Japan, and the USA. SH-655603-AA Printed in Germany by medicalvision. www.bostonscientific.eu/ACURATEneo © 2019 Boston Scientific Corporation or its affiliates. All rights reserved. DINSH0243EA
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
-
Length of Stay with ACURATE neo vs. Evolut™ R
ACURATE neo Aortic Valve System – Clinical Data
Clinical Highlights
Study Design
Routine use of the ACURATE neo self-expanding valve is associated with improved procedural outcomes and reduced post-operative length of stay: Insights from a single-center registry (ACURATE neo vs. Evolut R)
Kotronias RA, Banning AP, Kharbanda RK. Oxford University Hospital. Presented at EuroPCR 2019 by R. A. Kotronias.
Single-center study from Oxford, Great Britain, evaluating the impact of valve selection on procedural outcomes, length of stay (LoS), and 30-day mortality in 231 patients treated with either ACURATE neo (n = 143) or Evolut R (n = 88) between March 2017 and September 2018.
ACURATE neo demonstrates reduced post-operative complications and permanent pacemaker rates and comparable mortality and stroke rates vs. Evolut R
Improvements in procedural outcomes with ACURATE neo are associated with reductions in post-operative length of stay A multivariate linear regression model identified peri-procedural complications, pre-existing RBBB, and new permanent pacemaker implantation as independent predictors of post-operative length of stay.
3 3 32 2
In-hospital mortality
30-day mortality
0
Stroke
10
29
8 9
New PPI after TAVI
1 1
Life- threatening
bleeding
Major vascular
complications
ACURATE neo (n = 143) Evolut R (n = 88)
ACURATE neo
0
1
2
3
4
5
6
7
8
9
10
Evolut R
Post-Operative Length of StayProcedural Outcomes
Leng
th o
f sta
y (d
ays)
% o
f pat
ient
s
aOR 0.16 (0.05–0.5)
aOR 0.14 (0.01–0.68)
aOR 0.14 (0.03–0.68)
30
35
20
25
15
10
5
0
All trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority product registrations. Not intended for use or distribution in France, Japan, and the USA. SH-655603-AA Printed in Germany by medicalvision.
www.bostonscientific.eu/ACURATEneo © 2019 Boston Scientific Corporation or its affiliates. All rights reserved. DINSH0243EA
Related Documents
